Well being. Pfizer and BioNTech are testing a vaccine focusing on Covid and flu

Well being. Pfizer and BioNTech are testing a vaccine focusing on Covid and flu

The American pharmaceutical big Pfizer and its German accomplice BioNTech introduced on Thursday the launch of the primary part of a trial of a vaccine candidate based mostly on messenger RNA combining safety towards influenza and Covid-19.

Different labs try the mixture vaccine

The 2 laboratories have already developed one of many best-selling Covid vaccines on this planet.

A mix vaccine from mRNA know-how “may simplify vaccination practices towards these two respiratory pathogens, probably main to higher vaccination protection for each illnesses,” mentioned Annaliesa Anderson, chief scientific officer at Pfizer, in a press release. communicated.

Pfizer and BioNTech be part of different laboratories that are additionally making an attempt to develop a mixed vaccine: the American Moderna has began part 1 of a vaccine towards influenza and Covid, he confirmed on Thursday on the sidelines of the announcement of its quarterly outcomes.

In mid-October, the American biotechnology laboratory Novavax introduced the “optimistic outcomes of the part 1 and a pair of scientific trial” of a vaccine candidate of this kind.

180 volunteers

By 2020, BioNTech and Pfizer had been capable of shortly and efficiently create the world’s first accredited Covid-19 vaccine, which generated billions of {dollars} in income for each corporations.

The corporate from Mainz (West Germany) can be answerable for testing the security, the immune response and the optimum dose stage of a mixed candidate vaccine, by recruiting 180 wholesome volunteers aged 18 to 64 in the USA. United, in response to a press launch. The follow-up interval for every participant can be six months.

Messenger RNA is used to command human cells to fabricate proteins current within the virus so as to accustom the immune system to acknowledge and neutralize it.

The testing part will serve to uncover “the potential of mRNA vaccines focusing on a couple of pathogen,” Ugur Sahin, CEO and co-founder of BioNTech, mentioned within the assertion.

#Well being #Pfizer #BioNTech #testing #vaccine #focusing on #Covid #flu

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button